Trimethoprim and nitrofurantoin POM-to-P switches abandoned
Applications to reclassify trimethoprim and nitrofurantoin to over-the-counter status have been withdrawn by the drug companies behind the switch requests.
Actavis has confirmed that its application to make its trimethoprim preparation Cysticlear a pharmacy medicine for the treatment of urinary tract infections has been withdrawn. Goldshield also confirmed that it has withdrawn its request to reclassify its nitrofurantoin product Cystobid for the same indication.
The switch applications had attracted criticism from experts, including the British Society for Antimicrobial Chemotherapy, which is concerned about the development of antimicrobial resistance and the control and prevention of Clostridium difficile infection (PJ Online, 1 September 2008).
A spokeswoman for Actavis was unable to give a reason for the withdrawal but said that the company will continue to pursue its POM-to-P pipeline in other therapeutic areas.
Citation: The Pharmaceutical Journal URI: 11008849
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com